Dare Bioscience Inc (DARE) Stock Price, Quote & News

Company Profile

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual aro...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 926 7655

Website: darebioscience.com

Address:

3655 Nobel Drive, Suite 260, San Diego, United States

HMIC Mar. 20 at 10:19 AM

$DARE

0 · Reply

Ceri78 Mar. 19 at 7:53 PM

$DARE constant dilution, I can’t understand who is putting more money on that turd

1 · Reply

HMIC Mar. 19 at 6:20 PM

$DARE Just a reminder of where this stock can go .

1 · Reply

BuyAndHoldStocks Mar. 18 at 6:14 AM

$DARE 💵 Nice - In connection therewith, we issued an aggregate of 43,050 Investor Units consisting of 43,050 shares of Series A Preferred Stock and Investor Warrants to purchase up to 86,100 shares of our common stock. https://ir.darebioscience.com/static-files/1bf5f603-f922-4892-bc8d-cb9d01ed9fe7

0 · Reply

BuyAndHoldStocks Mar. 17 at 6:09 PM

$DARE Then add their other assets in the pipeline and also revenues from Dare to Play - rNPV could be many times higher than what can be estimated for Ovaprene. No advice.

0 · Reply

BuyAndHoldStocks Mar. 17 at 4:46 PM

$DARE Yesterday’s price action strongly suggests a liquidity sweep combined with clear absorption, indicating that larger participants were likely accumulating shares into weakness rather than distributing. When short sellers sell the stock, it’s like they’re carrying around a financial bomb. As long as the price stays relatively flat or slowly declines, it ticks quietly — but if the stock gaps up one morning, it can explode in the form of margin calls and panic covering. 💣📈 Liquidity is gone. Shorts stuck, long traders sold, market makers stranded. With no options to hedge, this stock is a ticking time bomb—any move could blow it up! 💣⚡ In these setups, the danger isn’t only being wrong on direction — it’s being unable to exit without causing a self-reinforcing move against your position. ☠️

0 · Reply

BuyAndHoldStocks Mar. 17 at 4:15 PM

$DARE The documentary provides non-dilutive awareness, category expansion, and narrative support, all of which can positively impact long-term adoption, brand equity, and investor sentiment toward Dare. https://www.docnyc.net/film/the-pink-pill-sex-drugs-who-has-control/

1 · Reply

BuyAndHoldStocks Mar. 17 at 4:13 PM

$DARE Investor-focused summary of how the documentary (“The Pink Pill”) can generate positive attention signals for Dare and Dare to Play: https://nation.africa/kenya/life-and-style/the-pink-pill-long-battle-to-bring-addyi-first-libido-drug-for-women-to-market-5392732?utm_source=twitter&utm_medium=dn_social Investor Takeaways 1. Category validation & market awareness The film elevates female sexual health—specifically HSDD—from a niche issue to a mainstream, discussable condition. 👉 Signals growing addressable market awareness and reduced stigma → potential demand expansion. 2. Demand creation through normalization By sharing real patient stories, the documentary helps normalize low libido as a treatable condition. 👉 Likely to drive patient self-identification and physician engagement, supporting uptake.

1 · Reply

BuyAndHoldStocks Mar. 17 at 9:39 AM

$DARE ”The market's current valuation reflects this capital structure. With the stock trading around $1.47, the company carries a market capitalization consistent with a pre-clinical asset. This is the price of patience. The market is not yet pricing in the multi-indication platform potential or the significant non-dilutive funding already secured. Instead, it is valuing Daré as a single-product, early-stage company. For investors, this creates a unique setup: the stock price is low enough to absorb the risk of a single clinical failure, while the grant-funded runway provides ample time for the platform's broader applications to be tested. The financial runway is now long enough to see if this is a paradigm shift or just another pipeline.” https://www.bitget.com/amp/news/detail/12560605270886

0 · Reply

DARKP00L Mar. 16 at 8:32 PM

$DARE

0 · Reply

Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth

Mar 12, 2026, 8:00 AM EDT - 9 days ago

Daré Bioscience Participates in Virtual Investor “What This Means” Segment

Feb 23, 2026, 8:00 AM EST - 26 days ago

Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer

Dec 10, 2025, 8:00 AM EST - 3 months ago

DARE to PLAY™ Sildenafil Cream Now Available for Pre-Order by Prescription: First Evidence-Based Topical Arousal Cream for Women Begins Commercial Rollout in Select States via 503B Outsourcing Facility

Nov 13, 2025, 4:01 PM EST - 4 months ago

Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 6, 2025, 8:00 AM EST - 4 months ago

Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025

Sep 24, 2025, 8:00 AM EDT - 6 months ago

Daré Bioscience to Receive up to $499,000 to Support Preeclampsia Research

Aug 14, 2025, 4:01 PM EDT - 7 months ago

Daré Bioscience Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 7, 2025, 8:00 AM EDT - 8 months ago

Daré Bioscience to Host Second Quarter 2025 Financial Results and Company Update Conference Call and Webcast on August 14, 2025

Jul 29, 2025, 8:00 AM EDT - 8 months ago

Daré Bioscience and Rosy Wellness Launch First Phase of Patient-Focused Campaign to Support DARE to PLAY™ Sildenafil Cream

Jul 21, 2025, 1:47 PM EDT - 8 months ago

UPDATE - Daré Bioscience to Host August 6 Webinar: The DARE to PLAY™ Difference - The Sildenafil Cream That Raises the Bar

Jul 14, 2025, 1:09 PM EDT - 8 months ago

Crude Oil Moves Lower; Daré Bioscience Shares Jump

Jul 14, 2025, 8:00 AM EDT - 8 months ago

Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive

Jul 11, 2025, 8:00 AM EDT - 9 months ago

Daré Bioscience Receives $6 Million Non-Dilutive Grant Installment; $37.8M to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic Disorders

Jun 12, 2025, 5:00 PM EDT - 10 months ago

Daré Bioscience Announces Adjournment of Annual Meeting of Stockholders

May 13, 2025, 4:01 PM EDT - 11 months ago

Daré Bioscience Reports First Quarter 2025 Financial Results and Provides Company Update

Mar 31, 2025, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports Full Year 2024 Financial Results and Provides Company Update

Mar 24, 2025, 8:00 AM EDT - 1 year ago

Daré Bioscience to Host Full Year 2024 Financial Results and Company Update Conference Call and Webcast on March 31, 2025

Feb 6, 2025, 8:00 AM EST - 1 year ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID) to Support DARE-HPV Development

Jan 9, 2025, 8:00 AM EST - 1 year ago

Daré Bioscience to Participate in the Women's Health Series at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 14, 2024, 4:01 PM EST - 1 year ago

Daré Bioscience Reports Third Quarter 2024 Financial Results and Provides Company Update

Nov 7, 2024, 8:00 AM EST - 1 year ago

Daré Bioscience to Host Third Quarter 2024 Financial Results and Company Update Conference Call and Webcast on November 14, 2024

Oct 23, 2024, 12:30 PM EDT - 1 year ago

Daré Bioscience Selected to Receive $10 Million Award from ARPA-H's Sprint for Women's Health

Oct 21, 2024, 8:05 AM EDT - 1 year ago

Daré Bioscience Announces Common Stock Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Daré Bioscience Reports Second Quarter 2024 Financial Results and Provides Company Update

Jul 19, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Regains Compliance with Nasdaq Minimum Bid Price Rule

Jul 1, 2024, 6:54 AM EDT - 1 year ago

Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors

KPRX

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Daré Bioscience Announces Reverse Stock Split

May 14, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update

May 2, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network

Apr 30, 2024, 7:30 AM EDT - 2 years ago

Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women's Health Product Candidates through Key Catalysts

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1

Apr 11, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Mar 28, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

Mar 21, 2024, 8:00 AM EDT - 2 years ago

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

Mar 15, 2024, 2:33 PM EDT - 2 years ago

This overlooked corner of women's health could be a $350 billion market opportunity

PFE PGNY VTGN BTMD

Jan 31, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

Jan 26, 2024, 4:30 PM EST - 2 years ago

Daré Bioscience Announces Executive Team and Board of Directors Changes

Jan 17, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Grant to Support Biotherapeutic Product Development

Jan 4, 2024, 8:00 AM EST - 2 years ago

Daré Bioscience's DARE-LARC1 Platform Technology Achieves Proof-of-Concept Device that has Transformative Potential for Women's Health as well as in Treating a Broad Range of Diseases

Dec 26, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Secures $12 million in Royalty-backed Investment Structure

Dec 20, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study

Dec 13, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Announces Funding Award Notice from the National Institutes of Health (NIH) Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) to Support DARE-PTB1 Phase 1 Human Clinical Study

Nov 9, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update

Nov 6, 2023, 8:00 AM EST - 2 years ago

Daré Bioscience to Participate in Three November Conferences

Nov 1, 2023, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Additional Positive Data from Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women and Proposed Endpoints and Patient Population for Phase 3 Program

Aug 30, 2023, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces $7.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Aug 10, 2023, 8:00 AM EDT - 2 years ago

Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update

Aug 9, 2023, 8:00 AM EDT - 2 years ago

Daré Bioscience Announces Publication in The Journal of The North American Menopause Society of Positive Efficacy Findings for the Treatment of Menopausal Symptoms from a Phase 1/2 Clinical Trial of DARE-HRT1 Intravaginal Rings

Aug 3, 2023, 8:00 AM EDT - 2 years ago

Daré Bioscience to Host Second Quarter 2023 Financial Results and Company Update Conference Call and Webcast on August 10, 2023

HMIC Mar. 20 at 10:19 AM

$DARE

0 · Reply

Ceri78 Mar. 19 at 7:53 PM

$DARE constant dilution, I can’t understand who is putting more money on that turd

1 · Reply

HMIC Mar. 19 at 6:20 PM

$DARE Just a reminder of where this stock can go .

1 · Reply

BuyAndHoldStocks Mar. 18 at 6:14 AM

0 · Reply

BuyAndHoldStocks Mar. 17 at 6:09 PM

$DARE Then add their other assets in the pipeline and also revenues from Dare to Play - rNPV could be many times higher than what can be estimated for Ovaprene. No advice.

0 · Reply

BuyAndHoldStocks Mar. 17 at 4:46 PM

0 · Reply

BuyAndHoldStocks Mar. 17 at 4:15 PM

1 · Reply

BuyAndHoldStocks Mar. 17 at 4:13 PM

1 · Reply

BuyAndHoldStocks Mar. 17 at 9:39 AM

0 · Reply

DARKP00L Mar. 16 at 8:32 PM

$DARE

0 · Reply

BuyAndHoldStocks Mar. 16 at 4:59 PM

$DARE 💡 A very strong signal pattern that many experienced traders watch for in DARE and similar stocks is called: “seller exhaustion + bid stepping up.” When this happens, a stock can sometimes explode upward within minutes. 🔥 20k was absorbed at 1.42 and went through the Dark Pool. OBV Dark Pool is now minus 23k after DP bought back a bit.

0 · Reply

BuyAndHoldStocks Mar. 16 at 1:07 PM

$DARE 📈⏳🕛💡 👇💡

0 · Reply

BuyAndHoldStocks Mar. 16 at 12:52 PM

$DARE Prepared to start recruiting. Relatively short study time. https://clinicaltrials.gov/study/NCT06668896?term=Dar%C3%A9%2520Bioscience,%2520Inc&rank=9

0 · Reply

DARKP00L Mar. 16 at 12:13 PM

$DARE 08:08 on Mar. 16 2026 Daré Bioscience Gets ~$2M Funding From National Institutes Of Health's Division For Its Intravaginal Ring DARE-PTB1 For Prevention Of Preterm Birth #tradeideas

0 · Reply

BuyAndHoldStocks Mar. 15 at 6:58 PM

$DARE If Organon is investing in TikTok marketing for Xaciato, they clearly expect a return — this has likely been part of the launch strategy from the start. https://itsdovi.com/#/organon-xaciato/ Stronger sales acceleration could potentially trigger milestone payments. XOMA (Daré) is eligible for up to $182.5M in milestones plus tiered double-digit royalties on net sales. 💰 Xaciato also has QIDP status from the U.S. Food and Drug Administration, which provides extended market exclusivity in the U.S. On top of that, Organon has partnered with Evvy. Women diagnosed with bacterial vaginosis via Evvy’s at-home test can get a prescription for Xaciato directly through the platform — potentially enabling same-day treatment without a clinic visit.

0 · Reply

BuyAndHoldStocks Mar. 15 at 2:04 PM

$DARE Daré received $22M in gross proceeds at closing. After XOMA achieves a pre-specified total return, Daré will receive milestone payments equal to 50% of all remaining cash flows sold to XOMA under the agreement. As of Q3 2025, XOMA had received about $0.5M from the asset. I don’t expect XACIATO to materially impact Daré in the near term, but if the commercial ramp accelerates in 2026, it could become meaningful for Daré by 2027. The market opportunity is substantial. Bacterial vaginosis (BV) affects roughly 21 million women, and the symptoms are often mistaken for a yeast infection, suggesting significant underdiagnosis and treatment potential. XOMA reports earnings on March 18, which should provide a clearer picture of the current growth trajectory.

0 · Reply

BuyAndHoldStocks Mar. 15 at 1:46 PM

$DARE ”Once biological differences become measurable, they become actionable. By bringing modern microbiome science into BV care, this research lays the groundwork for more precise studies, more effective treatments, and ultimately better reproductive health outcomes.” https://www.evvy.com/blog/bv-subtypes-research

0 · Reply

BuyAndHoldStocks Mar. 15 at 1:43 PM

$DARE ”Advancing biological resolution in BV care reflects a broader commitment to bringing precision medicine into women’s health at scale. For the millions affected each year, a deeper understanding offers a path toward more predictable care, longer-lasting relief, and stronger reproductive confidence.” https://www.evvy.com/blog/bv-microbial-diversity-subtypes-research

0 · Reply

BuyAndHoldStocks Mar. 15 at 1:31 PM

$DARE 💡 By integrating testing, diagnosis, and prescription into a digital care pathway, the partnership meaningfully lowers barriers to treatment and could accelerate adoption. As Evvy’s user base continues to grow, the platform has the potential to become a powerful commercial channel, positioning XACIATO for a significant sales ramp in 2026 and beyond. 🚀📈 https://www.futurefemhealth.com/p/organon-and-evvy-team-up-to-broaden

0 · Reply

BuyAndHoldStocks Mar. 15 at 1:30 PM

$DARE 💡💡2026 could mark the inflection point for XACIATO’s commercial ramp. Through its partnership with Evvy, the product is gaining access to one of the fastest-growing platforms in vaginal microbiome testing and digital women’s health. Evvy reported more than 75,000 patients and 2,000 healthcare providers on its platform as of October 2025, and further expanded its ecosystem with the launch of an at-home clinical care program in December 2025. https://www.evvy.com/blog/why-how-we-built-clinical-care-with-evvy The collaboration enables women diagnosed with bacterial vaginosis through Evvy’s at-home testing to obtain prescriptions for XACIATO—a single-dose treatment developed by Organon—directly through the platform. This streamlined model allows for potential same-day diagnosis and treatment without requiring an in-person clinic visit. https://wewillcure.com/insights/company-profiles/womens-health-startups-to-watch-in-2026

0 · Reply

BuyAndHoldStocks Mar. 15 at 11:41 AM

$DARE The session closed with a record-low trading volume of only 53 shares, indicating that market liquidity is effectively nonexistent. This creates an asymmetric risk profile for short sellers. 💀 As liquidity tightens, attempts to cover positions can themselves generate incremental demand and signal strengthening market interest. Rather than facilitating orderly exits, covering activity may contribute to upward price pressure and reinforce positive price momentum. In extreme cases, this dynamic can evolve into a reflexive feedback loop in which limited supply, rising prices, and short covering interact to accelerate

0 · Reply

BuyAndHoldStocks Mar. 15 at 9:14 AM

$DARE Additional publicity in Women’s World highlights the potential of sildenafil cream for women. Considering Dare’s active presence at multiple conferences, it is reasonable to assume that awareness among physicians is increasing and that prescriptions may already be starting. See Dare’s Instagram for examples of how they have actively promoted Dare to Play. https://www.womansworld.com/wellness/how-scream-cream-is-boosting-arousal-for-women-over-50 💡 Women Are Buzzing About ‘Scream Cream’—Doctors Say It May Boost Arousal Fast

0 · Reply

Market Cap	20.01M
Revenue (ttm)	10,000.00
Net Income (ttm)	-4.05M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	1.14
Profit Margin	-40,500.00%
Debt to Equity Ratio	0.00

Volume	204,800
Avg Vol	75,236
Day's Range	N/A - N/A
Shares Out	14.29M
Stochastic %K	32%
Beta	0.96
Analysts	Strong Sell
Price Target	$10.75